Physician profile
Daniel Yao
NPI 1619048972
$8,155.37
in general payments reported to CMS, 2019-2025
12 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $334 · 2021: $4,427 · 2022: $750 · 2024: $1,423 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.07 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,750.00 | 2019-2021 | |
| Edap Technomed INC | $1,242.00 | 2024 | |
| Dentsply Sirona INC | $650.00 | 2022 | |
| Janssen Biotech, INC. | $389.06 | 2019-2025 | Akeega, Erleada, Rybrevant |
| Dornier Medtech America, INC | $324.05 | 2021-2022 | |
| Astellas Pharma US INC | $211.69 | 2019-2020 | |
| Boston Scientific Corporation | $193.00 | 2021-2025 | Spaceoar Vue System - 10ml |
| Pfizer INC. | $190.13 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $116.05 | 2025 | Adstiladrin |
| Procept Biorobotics Corporation | $40.40 | 2021-2024 | Aquabeam System |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Progenics Pharmaceuticals, INC. | $13.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.